Oct. 16 at 1:11 PM
$ADGM 25M shares ×
$1.36 = ~
$34M market cap, backed by ~
$23M in cash and full funding secured through milestone warrants to reach FDA approval. With financing risk removed, potential competitors are now likely to take the company far more seriously—creating an ideal setup for a strategic suitor to sign an NDA, review unpublished data (such as 6-month freedom from recurrent sustained MMVT in 50%+ of subjects), and pursue a buyout before any milestone shares are issued